blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2930170

EP2930170 - PYRIDONE COMPOUND FOR USE IN THE TREATMENT OF DERMATOLOGICAL DISORDERS [Right-click to bookmark this link]
Former [2015/42]PYRIDONE COMPOUND
[2018/36]
StatusNo opposition filed within time limit
Status updated on  11.12.2020
Database last updated on 19.10.2024
FormerThe patent has been granted
Status updated on  03.01.2020
FormerGrant of patent is intended
Status updated on  12.03.2019
FormerExamination is in progress
Status updated on  12.02.2019
FormerGrant of patent is intended
Status updated on  27.09.2018
FormerExamination is in progress
Status updated on  13.04.2018
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Kyowa Kirin Co., Ltd.
1-9-2, Otemachi
Chiyoda-ku
Tokyo 100-0004 / JP
[2019/51]
Former [2015/42]For all designated states
Kyowa Hakko Kirin Co., Ltd.
1-6-1, Ohtemachi Chiyoda-ku
Tokyo 100-8185 / JP
Inventor(s)01 / NAKAMURA, Rina
c/o Head Office
Kyowa Kirin Co., Ltd.
1-9-2, Otemachi
Chiyoda-ku
Tokyo 100-0004 / JP
02 / ARATAKE, Seiji
c/o Head Office
Kyowa Kirin Co., Ltd.
1-9-2, Otemachi
Chiyoda-ku
Tokyo 100-0004 / JP
03 / UCHIDA, Kenji
c/o Head Office
Kyowa Kirin Co., Ltd.
1-9-2, Otemachi
Chiyoda-ku
Tokyo 100-0004 / JP
04 / UENO, Kimihisa
c/o Head Office
Kyowa Kirin Co., Ltd.
1-9-2, Otemachi
Chiyoda-ku
Tokyo 100-0004 / JP
05 / MOTOSAWA, Maasa
c/o Head Office
Kyowa Kirin Co., Ltd.
1-9-2, Otemachi
Chiyoda-ku
Tokyo 100-0004 / JP
06 / KABEYA, Takahiro
c/o Head Office
Kyowa Kirin Co., Ltd.
1-9-2, Otemachi
Chiyoda-ku
Tokyo 100-0004 / JP
 [2019/50]
Former [2015/42]01 / NAKAMURA, Rina
c/o Head Office
Kyowa Hakko Kirin Co. Ltd.
1-6-1 Ohtemachi
Chiyoda-ku
Tokyo 100-8185 / JP
02 / ARATAKE, Seiji
c/o Head Office
Kyowa Hakko Kirin Co. Ltd.
1-6-1 Ohtemachi
Chiyoda-ku
Tokyo 100-8185 / JP
03 / UCHIDA, Kenji
c/o Head Office
Kyowa Hakko Kirin Co. Ltd.
1-6-1 Ohtemachi
Chiyoda-ku
Tokyo 100-8185 / JP
04 / UENO, Kimihisa
c/o Head Office
Kyowa Hakko Kirin Co. Ltd.
1-6-1 Ohtemachi
Chiyoda-ku
Tokyo 100-8185 / JP
05 / MOTOSAWA, Maasa
c/o Head Office
Kyowa Hakko Kirin Co. Ltd.
1-6-1 Ohtemachi
Chiyoda-ku
Tokyo 100-8185 / JP
06 / KABEYA, Takahiro
c/o Head Office
Kyowa Hakko Kirin Co. Ltd.
1-6-1 Ohtemachi
Chiyoda-ku
Tokyo 100-8185 / JP
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[2015/42]
Application number, filing date13860161.206.12.2013
[2015/42]
WO2013JP82763
Priority number, dateJP2012026700806.12.2012         Original published format: JP 2012267008
[2015/42]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014088085
Date:12.06.2014
Language:JA
[2014/24]
Type: A1 Application with search report 
No.:EP2930170
Date:14.10.2015
Language:EN
[2015/42]
Type: B1 Patent specification 
No.:EP2930170
Date:05.02.2020
Language:EN
[2020/06]
Search report(s)International search report - published on:JP12.06.2014
(Supplementary) European search report - dispatched on:EP25.04.2016
ClassificationIPC:C07D213/82, A61K31/4545, A61P17/00, A61P17/02, A61P17/06, A61P17/10, A61P17/16, A61P43/00, C07D401/06, C07D401/12, C07D405/14, C07D409/14, C07D413/14, C07D491/107, C07D213/74, C07D401/14, C07D417/14
[2016/21]
CPC:
C07D401/06 (EP,CN,US); C07D401/14 (EP,CN,US); A61K31/4545 (EP,US);
A61P17/00 (EP); A61P17/02 (EP); A61P17/06 (EP);
A61P17/10 (EP); A61P17/16 (EP); A61P43/00 (EP);
C07D213/74 (EP,CN,US); C07D213/82 (EP,CN,US); C07D401/12 (EP,CN,US);
C07D405/14 (EP,CN,US); C07D409/14 (EP,CN,US); C07D413/14 (EP,CN,US);
C07D417/14 (EP,CN,US); C07D491/107 (EP,CN,US) (-)
Former IPC [2015/42]C07D213/82, A61K31/4545, A61P17/00, A61P17/02, A61P17/06, A61P17/10, A61P17/16, A61P43/00, C07D401/06, C07D401/12, C07D405/14, C07D409/14, C07D413/14, C07D491/107
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/42]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:PYRIDONVERBINDUNG ZUR VERWENDUNG IN DER BEHANDLUNG VON HAUT ERKRANKUNGEN[2019/14]
English:PYRIDONE COMPOUND FOR USE IN THE TREATMENT OF DERMATOLOGICAL DISORDERS[2018/36]
French:COMPOSÉ PYRIDONE POUR LE TRAITEMENT DES MALADIES DE LA PEAU[2018/36]
Former [2015/42]PYRIDONVERBINDUNG
Former [2015/42]PYRIDONE COMPOUND
Former [2015/42]COMPOSÉ PYRIDONE
Entry into regional phase06.07.2015Translation filed 
06.07.2015National basic fee paid 
06.07.2015Search fee paid 
06.07.2015Designation fee(s) paid 
06.07.2015Examination fee paid 
Examination procedure06.07.2015Examination requested  [2015/42]
18.11.2016Amendment by applicant (claims and/or description)
13.04.2018Despatch of a communication from the examining division (Time limit: M04)
13.07.2018Reply to a communication from the examining division
28.09.2018Communication of intention to grant the patent
01.02.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
13.03.2019Communication of intention to grant the patent
29.08.2019Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
07.11.2019Fee for grant paid
07.11.2019Fee for publishing/printing paid
07.11.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  13.04.2018
Opposition(s)06.11.2020No opposition filed within time limit [2021/02]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
07.11.2019Request for further processing filed
07.11.2019Full payment received (date of receipt of payment)
Request granted
07.11.2019Decision despatched
Fees paidRenewal fee
22.12.2015Renewal fee patent year 03
23.12.2016Renewal fee patent year 04
21.12.2017Renewal fee patent year 05
19.12.2018Renewal fee patent year 06
19.12.2019Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU06.12.2013
AL05.02.2020
AT05.02.2020
CY05.02.2020
CZ05.02.2020
DK05.02.2020
EE05.02.2020
ES05.02.2020
FI05.02.2020
HR05.02.2020
IT05.02.2020
LT05.02.2020
LV05.02.2020
MC05.02.2020
MK05.02.2020
MT05.02.2020
NL05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SE05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
TR05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
[2022/31]
Former [2022/30]HU06.12.2013
AL05.02.2020
AT05.02.2020
CY05.02.2020
CZ05.02.2020
DK05.02.2020
EE05.02.2020
ES05.02.2020
FI05.02.2020
HR05.02.2020
IT05.02.2020
LT05.02.2020
LV05.02.2020
MC05.02.2020
MT05.02.2020
NL05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SE05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
TR05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2022/27]HU06.12.2013
AT05.02.2020
CY05.02.2020
CZ05.02.2020
DK05.02.2020
EE05.02.2020
ES05.02.2020
FI05.02.2020
HR05.02.2020
IT05.02.2020
LT05.02.2020
LV05.02.2020
MC05.02.2020
MT05.02.2020
NL05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SE05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
TR05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2022/26]AT05.02.2020
CZ05.02.2020
DK05.02.2020
EE05.02.2020
ES05.02.2020
FI05.02.2020
HR05.02.2020
IT05.02.2020
LT05.02.2020
LV05.02.2020
MC05.02.2020
NL05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SE05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
TR05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2021/40]AT05.02.2020
CZ05.02.2020
DK05.02.2020
EE05.02.2020
ES05.02.2020
FI05.02.2020
HR05.02.2020
IT05.02.2020
LT05.02.2020
LV05.02.2020
MC05.02.2020
NL05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SE05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2021/10]AT05.02.2020
CZ05.02.2020
DK05.02.2020
EE05.02.2020
ES05.02.2020
FI05.02.2020
HR05.02.2020
IT05.02.2020
LT05.02.2020
LV05.02.2020
NL05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SE05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2020/50]CZ05.02.2020
DK05.02.2020
EE05.02.2020
ES05.02.2020
FI05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
NL05.02.2020
RO05.02.2020
RS05.02.2020
SE05.02.2020
SK05.02.2020
SM05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2020/49]CZ05.02.2020
DK05.02.2020
ES05.02.2020
FI05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
NL05.02.2020
RO05.02.2020
RS05.02.2020
SE05.02.2020
SK05.02.2020
SM05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2020/48]DK05.02.2020
ES05.02.2020
FI05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
NL05.02.2020
RO05.02.2020
RS05.02.2020
SE05.02.2020
SM05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2020/47]DK05.02.2020
ES05.02.2020
FI05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
NL05.02.2020
RS05.02.2020
SE05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2020/45]FI05.02.2020
HR05.02.2020
LV05.02.2020
NL05.02.2020
RS05.02.2020
SE05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2020/40]FI05.02.2020
HR05.02.2020
LV05.02.2020
RS05.02.2020
SE05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2020/39]FI05.02.2020
HR05.02.2020
LV05.02.2020
RS05.02.2020
SE05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
PT28.06.2020
Former [2020/38]FI05.02.2020
HR05.02.2020
LV05.02.2020
RS05.02.2020
SE05.02.2020
NO05.05.2020
GR06.05.2020
PT28.06.2020
Former [2020/37]FI05.02.2020
HR05.02.2020
LV05.02.2020
RS05.02.2020
SE05.02.2020
NO05.05.2020
PT28.06.2020
Former [2020/36]FI05.02.2020
RS05.02.2020
NO05.05.2020
PT28.06.2020
Former [2020/35]FI05.02.2020
NO05.05.2020
Documents cited:Search[I]US2003187020  (ASTLES PETER C [GB], et al) [I] 1-15 * example 163; claims 1, 55-57 *;
 [I]WO2004054974  (SMITHKLINE BEECHAM CORP [US], et al) [I] 1-15 * example 401; claims 1, 52 *;
 [ID]WO2006056427  (APPLIED RESEARCH SYSTEMS [NL], et al) [ID] 1-15 * page 33, line 20 - line 26; example 2; claims 1, 9 *;
 [I]EP1741702  (ONO PHARMACEUTICAL CO [JP]) [I] 1-15 * paragraph [[0085]]; examples 6(1), 17, 20, 46, 56(a), 56(b); claims 1, 21-23 *;
 [E]EP2927214  (KYOWA HAKKO KIRIN CO LTD [JP]) [E] 1-15* [4-(2-ethylphenylamino)-6-mercapto-5-methylpyridin-3-yl][4-(4-fluorophenyl)piperidin-1-yl]methanone; paragraph [[0412]] *
International search[X]JP2008520615  (LABORATOIRES SERONO SA);
 [X]JP2009511490  (EXELIXIS, INC.);
 [A]JP2011500698  (BOEHRINGER INGELHEIM INTERNATIONAL GMBH)
by applicantUS3849458
 JPS61275241
 JPS61277648
 JPS63198638
 JPH0519536B
 WO0196308
 WO0224650
 WO02053543
 WO03047577
 WO03070277
 WO03087366
 WO2005051301
 WO2005105743
 WO2006030032
 WO2006056427
 WO2006107860
 WO2006109876
 WO2013031931
    - NATURE REVIEWS IMMUNOLOGY, (2002), vol. 2, page 106
    - EXPERT OPINION ON INVESTIGATIONAL IDRUGS, (2010), vol. 19, page 345
    - EXPERT OPINION ON INVESTIGATIONAL DRUGS, (2010), vol. 19, page 345
    - CURRENT OPINION IN IMMUNOLOGY, (2001), vol. 13, page 670
    - JOURNAL OF INVESTIGATIVE DERMATOLOGY, (2009), vol. 129, page 2552
    - GENOMICS, (1994), vol. 23, page 609
    - PROTEIN CELL, (2012), vol. 3, page 571
    - CLINICAL DERMATOLOGY, (2008), vol. 26, page 539
    - JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (2006), vol. 118, page 178
    - NATURE MEDICINE, (2002), vol. 8, pages 157 - 165
    - INTERNATIONAL IMMUNOLOGY, (2006), vol. 18, pages 1233 - 1242
    - EUROPEAN JOURNAL OF IMMUNOLOGY, (2008), vol. 38, pages 647 - 657
    - EXPERIMENTAL DERMATOLOGY, (2007), vol. 17, pages 30 - 34
    - JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (2004), vol. 113, page 334
    - JOURNAL OF INVESTIGATIVE DERMATOLOGY, (2005), vol. 125, page 1149
    - NATURE IMMUNOLOGY, (2009), vol. 10, page 857
    - NATURE IMMUNOLOGY, (2009), vol. 10, page 864
    - EUROPEAN JOURNAL OF IMMUNOLOGY, (2008), vol. 38, page 647
    - Development of Pharmaceutical Product, HIROKAWA PUBLISHING INC., (1990), vol. 7, page 163
    - J. AM. CHEM. SOC., (2002), vol. 124, no. 10, page 2092
    - LIPIDS, (1974), vol. 9, no. 11, page 913
    - Jikken Kagaku Kouza, MARUZEN COMPANY, LIMITED, (2005), vol. 14, page 351
    - Jikken Kagaku Kouza, MARUZEN COMPANY, LIMITED, (2005), vol. 14, page 537
    - JOURNAL OF THE CHEMICAL SOCIETY, (1904), vol. 85, page 1760
    - AUSTRALIAN J. OF CHEMISTRY, (1999), vol. 52, page 1013
    - Jikken Kagaku Kouza, MARUZEN COMPANY, LIMITED, (2005), vol. 16, page 35
    - Jikken Kagaku Kouza, MARUZEN COMPANY, LIMITED, (2005), vol. 16, page 98
    - ANALYTICAL BIOCHEMISTRY, (2006), vol. 400, page 163
    - ANALYTICAL BIOCHEMISTRY (ANALY BIOCHEM, (2006), vol. 400, page 163
    - CYTOTECHNOLOGY, (1990), vol. 3, page 133
    - JOURNAL OF MEDICINAL CHEMISTRY, (2006), vol. 9, page 441
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.